STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Regulus Therapeutics Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Regulus Therapeutics Inc. (RGLS): Schedule 13G/A disclosure summarizing Point72 filings. Point72 Asset Management, Point72 Capital Advisors Inc. and Steven A. Cohen report beneficial ownership of 241,157 shares, representing 0.3% of the outstanding common stock on a diluted basis. The filing states these shares include shares issuable upon exercise of warrants and that Point72 entities hold shared voting and dispositive power over 241,157 shares with no sole voting or dispositive power. The ownership percentage is calculated using a total of 69,475,246 shares outstanding, which includes the 241,157 warrant shares.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: A small, non-controlling diluted stake (0.3%) disclosed by Point72; no material change to control or capital structure.

The filing reports 241,157 shares (0.3%) beneficially owned by Point72-related entities and Steven A. Cohen, including shares from warrants. Shared voting and dispositive power are reported; sole powers are zero. For investors, this is a routine 13G/A disclosure showing transparency about derivative-linked holdings. The size of the position is below 5% and therefore unlikely to be material to Regulus's governance or market dynamics.

TL;DR: Disclosure indicates shared control over a minor warrant-derived position; no implication of control intent.

The statement includes a certification that the securities were not acquired to change or influence control and identifies the reporting chain (investment manager, general partner, controlling individual). The classification of voting and dispositive powers as shared and the explicit inclusion of warrant-issuable shares align with standard disclosure practice. Given the 0.3% stake, this does not meet thresholds for control concerns under Section 13.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Includes 241,157 Shares (as defined in Item 2(a)) issuable upon exercise of warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 241,157 Shares issuable upon exercise of warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 241,157 Shares issuable upon exercise of warrants.


SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025

FAQ

How many Regulus Therapeutics (RGLS) shares do Point72 entities report owning?

The filing states Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen beneficially own 241,157 shares (including shares issuable upon exercise of warrants).

What percentage of RGLS does the 241,157-share position represent?

The position represents 0.3% of the outstanding common stock, calculated using 69,475,246 shares outstanding on a diluted basis.

Does the filing indicate sole voting or dispositive power over the shares?

No. The filing reports 0 sole voting power and 0 sole dispositive power, and 241,157 shared voting and shared dispositive power for the reporting persons.

Are the reported shares already outstanding or issuable upon exercise?

The filing explicitly states the 241,157 shares include shares issuable upon exercise of warrants.

Does the filing claim the position was acquired to influence control of RGLS?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
Regulus Therapeu

NASDAQ:RGLS

RGLS Rankings

RGLS Latest News

RGLS Latest SEC Filings

RGLS Stock Data

545.56M
67.29M
Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparations
Link
US
SAN DIEGO